Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00244426 | S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation | PHASE3 | COMPLETED | 1,372 | — | — | Dec 1, 2000 | Apr 1, 2008 | Dec 19, 2018 | 132 | Italy |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| indobufen | DRUG | Indobufen capsules 100 and 200mg |
| aspirin | DRUG | Acetylsalicylic acid capsules 300mg |
Inclusion Criteria: * Chronic or paroxysmal non rheumatic atrial fibrillation with cardioembolic risk factors: hypertension, ischemic cardiopathy, Congestive Heart Failure, diabetes mellitus Exclusion Criteria: * Clinically relevant organ disease * creatinine clearance \< 30 ml/min * gastric or d...